Alan Paciorek

Alan Paciorek

Auto-generated profile, based on publicly available information

Alan Paciorek

Department Epidemiology and Biostatistics and Department of Medicine, University of California San Francisco, San Francisco, CA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
EMElia J. Mmbaga
Elia J. Mmbaga
BMBeatrice Paul Mushi
Beatrice Paul Mushi
KDKatrina Deardorff
Katrina Deardorff
WMWilliam Mgisha
William Mgisha
LALarry Onyango Akoko
Larry Onyango Akoko
KLKatherine Van Loon
Katherine Van Loon
Background: East Africa is affected by a disproportionately high burden of esophageal squamous cell carcinoma (ESCC). Methods: We conducted an incident case–control study in Dar es Salaam, Tanzania with 1:1 matching for gender and age. A questionnaire evaluated known and putative risk factors for ESCC. Cochran–Mantel–Haenszel and multivariable conditional logistic regression analyses were applied to evaluate associations with ESCC risk, with adjustment for geographic zone. Results: Of 471 cases and 471 controls, the majority were male (69%); median ages were 59 and 55, respectively. In a multivariable logistic regression model, a low International Wealth Index (IWI) score [OR 2.57; 95% confidence interval (CI), 1.41–4.68], former smoking (OR 2.45; 95% CI, 1.46–4.13), second-hand smoke in the household (OR 1.67; 95% CI, 1.01–2.77), daily spicy chilies (OR 1.62; 1.04–2.52), and daily salted foods (OR 2.02; 95% CI, 1.06–3.85) were associated with increased risk of ESCC. Daily consumption of raw greens (OR 0.36; 95% CI, 0.16–0.80), fruit (OR 0.47; 95% CI, 0.27–0.82), and smoked fish (OR 0.31; 95% CI, 0.15–0.66) were protective. Permanent residence in the Central (OR 5.03; 95% CI, 2.16–11.73), Northern-Lake (OR 2.40; 95% CI, 1.46–3.94), or Southern Highlands zones (OR 3.18; 95% CI, 1.56–6.50) of Tanzania were associated with increased risk compared with residence in the Eastern zone. Conclusions: Low IWI score, smoke exposure(s), geographic zone, and dietary factors were associated with risk for ESCC in Tanzania. Impact: These findings will inform the development of future hypothesis-driven studies to examine risk factors for the high burden of ESCC in East Africa. See related commentary by McCormack et al., p. 248

3 February 2022 in JCO Global Oncology
Verified
Journal Article
Open access
GBGeoffrey C. Buckle
Geoffrey C. Buckle
EMElia J. Mmbaga
Elia J. Mmbaga
APAlan Paciorek
Alan Paciorek
LALarry Akoko
Larry Akoko
KDKatrina Deardorff
Katrina Deardorff
KLKatherine Van Loon
Katherine Van Loon
PURPOSE: Eastern Africa is one of several regions affected by high incidence rates of esophageal squamous cell carcinoma (ESCC). A unique epidemiologic feature of ESCC in Eastern Africa is the high incidence in young people, with one-third of cases diagnosed at age < 45 years. This study aimed to investigate risk factors for early-onset ESCC in Tanzania through a secondary analysis of a matched case-control study. MATERIALS AND METHODS: From 2013 to 2015, ESCC cases were recruited at Muhimbili National Hospital and Ocean Road Cancer Institute in Dar es Salaam, Tanzania. Hospital controls were identified from patients with nonmalignant conditions and matched 1:1 for sex and age (± 10 years). Questionnaires were used to assess sociodemographic characteristics and environmental, dietary, and lifestyle risk exposures. Multivariate logistic regression models were used to estimate age-specific odds ratios of ESCC for exposures among participants age 30-44 and ≥ 45 years. RESULTS: A total of 471 cases and 471 controls were enrolled. Among cases, 100 (21%) were < 45 years. Multiple exposures were identified as risk factors for early-onset ESCC, several of which were unique to this age group, including infrequent teeth cleaning, secondhand tobacco smoke exposure, and pest infestation of grain and/or nuts. Lower socioeconomic status, family history of ESCC, tobacco smoking, home-brewed alcohol consumption, home storage of grain and/or nuts, and use of firewood for cooking were associated in the older but not the younger age group. Hot beverage intake was associated with increased ESCC risk in both age groups. CONCLUSION: Our results suggest that ESCC risk factors in Tanzania vary between age groups. With the data currently available, environmental and behavioral risk factors appear to play an important role in the high incidence of ESCC among young people.

17 March 2023 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
BLBryan Khuong Le
Bryan Khuong Le
PMPatrick McGarrah
Patrick McGarrah
APAlan Paciorek
Alan Paciorek
AMAmr Mohamed
Amr Mohamed
AAAndrea B. Apolo
Andrea B. Apolo
Thorvardur HalfdanarsonThorvardur Halfdanarson
Thorvardur Halfdanarson
Primary urinary neuroendocrine neoplasms (U-NENs) are extremely rare thus optimal treatment is unknown. Grading and treatment are typically extrapolated from other primary sites. Since 2010, the clinical landscape for NENs has changed substantially. We performed a retrospective review of U-NENs to assess treatment patterns and oncologic outcomes of patients treated in the recent era of NEN therapy. A multicenter retrospective review of patients diagnosed after 2005 and alive after 2010. Time to treatment failure (TTF) was used to evaluate progression and toxicity for systemic therapy. Tumors were categorized as having either well-differentiated neuroendocrine tumor (WDNET) or poorly differentiated neuroendocrine carcinoma (PDNEC) histology. A total of 134 patients from 6 centers were included in our analysis, including 94 (70%) bladder, 32 (24%) kidney, 2 (1.5%) urethra and 4 other urinary primaries (3.0%). Poorly-differentiated neuroendocrine carcinoma was more common in bladder (92%) than non-bladder tumors (8%). Median Ki-67 available in bladder primary was 90% (n = 24), kidney 10% (n = 23), ureter 95% (n = 1), urethra 54% (n = 2), and others 90% (n = 3). Patients received a median of 2 therapies (range 0-10). Median time to death was not reached in locoregional WDNETs versus 8.2 years (95% CI, 3.5-noncalculable) in metastatic WDNETs (predominantly renal primary). Median time to death was 3.6 years (95% CI, 2.2-9.2) in locoregional PDNECs versus 1 year (95% CI, 0.8-1.3) in metastatic PDNECs (predominantly bladder primary). This is the most extensive series examining treatment patterns in patients with U-NENs in the recent era of NEN therapy. The apparent inferior survival for bladder NENs is likely due to the preponderance of PDNECs in this group. As predicted, treatments for U-NENs mirrored that of other more common NENs. In our retrospective cohort, we observed that patients with WD-UNETs treated with peptide receptor radionuclide therapy (PRRT) and everolimus suggested potential activity for disease control in WD-UNETs. Prospective studies are needed to assess the activity of new oncology drugs in UNENs.

1 July 2022 in JCO Global Oncology
Verified
Journal Article
Open access
JMJennifer Morgan
Jennifer Morgan
RDRebecca J. DeBoer
Rebecca J. DeBoer
JBJean Bosco Bigirimana
Jean Bosco Bigirimana
CNCam Nguyen
Cam Nguyen
DRDeogratias Ruhangaza
Deogratias Ruhangaza
CSCyprien Shyirambere
Cyprien Shyirambere
PURPOSE: In describing our ten-year experience with treating chronic myeloid leukemia (CML) as part of the Glivec Patient Assistance Program (GIPAP) in rural Rwanda, we evaluate (1) patient characteristics and treatment outcomes, (2) resource-adapted management strategies, and (3) the impact of diagnostic capacity development. METHODS: We retrospectively reviewed all patients with BCR-ABL–positive CML enrolled in this GIPAP program between 2009 and 2018. Clinical data were analyzed using descriptive statistics, Kaplan-Meier methods, proportional hazards regression, and the Kruskal-Wallis test. RESULTS: One hundred twenty-four patients were included. The median age at diagnosis was 34 (range 8-81) years. On imatinib, 91% achieved complete hematologic response (CHR) after a median of 49 days. Seven (6%) and 12 (11%) patients had primary and secondary imatinib resistance, respectively. The 3-year overall survival was 80% (95% CI, 72 to 87) for the cohort, with superior survival in imatinib responders compared with those with primary and secondary resistance. The median time from imatinib initiation to CHR was 59 versus 38 days ( P = .040) before and after in-country diagnostic testing, whereas the median time to diagnosis ( P = .056) and imatinib initiation ( P = .170) was not significantly different. CONCLUSION: Coupling molecular diagnostics with affordable access to imatinib within a comprehensive cancer care delivery program is a successful long-term strategy to treat CML in resource-constrained settings. Our patients are younger and have higher rates of imatinib resistance compared with historic cohorts in high-income countries. High imatinib resistance rates highlight the need for access to molecular monitoring, resistance testing, and second-generation tyrosine kinase inhibitors, as well as systems to support drug adherence. Hematologic response is an accurate resource-adapted predictor of survival in this setting. Local diagnostic capacity development has allowed for continuous, timely CML care delivery in Rwanda.

1 March 2026 in JCO Global Oncology
Verified
Journal Article
Open access
ANAslam Nkya
Aslam Nkya
MXMary Jue Xu
Mary Jue Xu
GPGodfrey Sama Philipo
Godfrey Sama Philipo
SHSummaiya Haddadi
Summaiya Haddadi
DNDianna Ng
Dianna Ng
KLKatherine Van Loon
Katherine Van Loon
PURPOSE: While the prevalence of human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HNSCC), specifically in the oropharynx subsite, is increasing in western populations, limited data exist on prevalence in sub-Saharan Africa. This study describes the prevalence and associated risk factors of HPV association among individuals with HNSCC presenting to Muhimbili National Hospital, the largest public tertiary referral center in Tanzania, a country in East Africa. METHODS: Participants with HNSCC presenting between July 2020 and June 2022 were prospectively recruited in this cross-sectional study. Tumor samples were tested for HPV DNA polymerase chain reaction (PCR) and p16 immunohistochemistry (IHC). Multivariate logistic regression models assessed potential risk factors for HPV. RESULTS: Among 121 individuals diagnosed with HNSCC, the median age was 55 years (IQR, 47-68 years), 76.0% (92/121) were male, and 10.9% (13/119 tested) were HIV positive. Among all cases of HNSCC, the prevalence of HPV was 14.6% (95% CI, 7.5 to 21.6) using PCR testing and 23.6% (95% CI, 15.5 to 31.7) using p16 IHC as a surrogate marker. For the oropharynx subsite, 23.1% (95% CI, 0.2 to 46.0) of specimens using PCR testing and 28.6% (95% CI, 4.9 to 52.2) using p16 IHC tested positive (Kappa 3.0 [95% CI, –51.1 to 57.1]; McNemar P value = .66). Factors independently associated with HPV positivity were oropharynx subsite (odds ratio [OR], 6.4 [95% CI, 1.0 to 40.6], P = .048), nonsmokers (OR, 6.4 [95% CI, 1.1 to 35.4], P = .035), and unmarried individuals (OR, 10.6 [95% CI, 2.4 to 47.3], P = .002). HPV association in HNSCC did not significantly differ by HIV status or sexual activity. CONCLUSION: HPV association in HNSCC, specifically of the oropharyngeal subsite, is lower in this cohort from Tanzania compared with western populations. Additional regional data are needed to inform clinical care guidelines and vaccination policies.

1 March 2025 in JCO Global Oncology
Verified
Journal Article
Open access
MTMusliu Adetola Tolani
Musliu Adetola Tolani
CAChristian Agbo Agbo
Christian Agbo Agbo
APAlan Paciorek
Alan Paciorek
SUShehu Salihu Umar
Shehu Salihu Umar
RORufus Wale Ojewola
Rufus Wale Ojewola
RDRebecca DeBoer
Rebecca DeBoer
PURPOSE: Optimal survival outcomes of prostate cancer are best achieved through high-quality care for curable disease. In Nigeria, various barriers may impede the curative treatment of prostate cancer, yet their impact on care and patient outcomes remains anecdotal. This study assessed treatment quality, survival outcomes, and interhospital differences of these metrics among patients with clinically localized prostate cancer in Nigeria. METHODS: A retrospective study of patients with clinical stage T1-T3a, M0 prostate cancer at three tertiary hospitals in Nigeria over a 3-year period was conducted. Data on hospital sites, sociodemographics, clinicopathologic characteristics, quality metrics, imaging used, treatment, and survival status were collected. The primary end point was time from diagnosis to first treatment. Secondary end points were time from presentation to diagnosis, other prostate cancer quality metrics, all-cause survival, and interhospital differences in these metrics. Quality of diagnostics, treatments, and other outcomes were described and compared using Cox regression. RESULTS: This study included 110 patients with a median age of 67 years. Most (n = 66, 61%) had high-risk disease. The median time from tertiary hospital presentation to diagnosis was 31 days. Median time from diagnosis to first treatment of any type was 68 days, with radical radiotherapy was 117 days, and with radical prostatectomy was 104 days. Eighteen percent (n = 20) had guideline-concordant imaging for tumor staging, 67 patients (61%) received any treatment or active surveillance, and retention in care was 42%. Three-year all-cause survival was 41%. There was a significant difference in most quality metrics including guideline-concordant imaging and treatment across the hospital sites. CONCLUSION: Time to treatment was delayed beyond international benchmarks; quality of staging, treatment, and care process were suboptimal; and survival was poor amid geographical disparities in care.